Characterization of a survival pathway controlled by FGFR4 in alveolar Rhabdomyosarcoma

被引：0
|
作者：
Wachtel, Marco
Schafer, Beat
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3418
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3418
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Antibody-based targeting of the cell surface receptor tyrosine kinase FGFR4 in rhabdomyosarcoma and other cancers
    Skarzynski, Martin
    Shivaprasad, Nitya
    Subramanian, Baskar
    Azorsa, David
    Zhu, Zhongyu
    Dimitrov, Dimiter
    Khan, Javed
    CANCER RESEARCH, 2017, 77
  • [32] The Role FGFR4 in Pancreatic Endocrine Tumors
    Serra, S.
    Ezzat, S.
    Chetty, R.
    Asa, S. L.
    LABORATORY INVESTIGATION, 2009, 89 : 120A - 120A
  • [33] First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
    Kim, R.
    Sharma, S.
    Meyer, T.
    Sarker, D.
    Macarulla, T.
    Sung, M.
    Choo, S. P.
    Shi, H.
    Schmidt-Kittlers, O.
    Clifford, C.
    Wolf, B.
    Llovet, J. M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S41 - S41
  • [34] Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
    Li, Samuel Q.
    Cheuk, Adam T.
    Shern, Jack F.
    Song, Young K.
    Hurd, Laura
    Liao, Hongling
    Wei, Jun S.
    Khan, Javed
    PLOS ONE, 2013, 8 (10):
  • [35] 靶向FGFR4的miRNA筛选
    高赢政
    蔡琳
    黄佳伟
    邱梦媛
    黄通周
    数理医药学杂志, 2017, 30 (06) : 791 - 794
  • [36] FGFR3 and FGFR4 mutational analyses in thyroid carcinoma
    Serra, S.
    Cheng, S.
    Ezzat, S.
    Asa, S. L.
    LABORATORY INVESTIGATION, 2008, 88 : 110A - 111A
  • [37] FGFR3 and FGFR4 mutational analyses in thyroid carcinoma
    Serra, S.
    Cheng, S.
    Ezzat, S.
    Asa, S. L.
    MODERN PATHOLOGY, 2008, 21 : 110A - 111A
  • [38] Exploring the involvement of FGFR4 in hepatocellular carcinoma
    Ho, Han Kiat
    Pok, Sharon
    Ruhe, Jens E.
    Hart, Stefan
    Streit, Sylvia S.
    Loo, Hooi Linn
    Foo, Priscilla
    Do Aung, Myat
    Ullrich, Axel
    Lim, Seng Gee
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3549S - 3550S
  • [39] Targeting FGFR4 in colorectal cancer cells
    Heinzle, Christine
    Erdem, Zeynep
    Sonvilla, Gudrun
    Staettner, Stefan
    Karner, Josef
    Klimpfinger, Martin
    Grasl-Kraupp, Bettina
    Holzmann, Klaus
    Grusch, Michael
    Berger, Walter
    Marian, Brigitte
    CANCER RESEARCH, 2012, 72
  • [40] A novel, potent and selective FGFR4 inhibitor, HM81422 in hepatocellular carcinoma with FGFR4-driven pathway activation
    Lee, Jaeho
    Kang, Hyunjeong
    Koo, Kyounghwa
    Ha, Youngeun
    Lim, Sun Young
    Byun, Joo-Yun
    Yu, Hyunkyung
    Song, Taehun
    Lee, Moonsub
    Jung, Seung Hyun
    Kim, Taewoo
    Bang, Hyojeong
    Kim, Eunyoung
    Kang, Jahoon
    Lee, Ho Jeong
    Kim, YoungHoon
    Ahn, YoungGil
    Suh, KweeHyun
    Kim, Sun-Jin
    CANCER RESEARCH, 2018, 78 (13)
12345